Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – Time to Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares saw unusually-strong trading volume on Friday . Approximately 294,592 shares changed hands during mid-day trading, an increase of 116% from the previous session’s volume of 136,389 shares.The stock last traded at $16.44 and had previously closed at $16.09.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ALPMY shares. Citigroup cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Four equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Astellas Pharma Stock Performance

The stock’s 50-day moving average is $14.67 and its 200-day moving average is $12.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.15. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. The firm had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.21 billion. On average, equities research analysts expect that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).